Response rates to monotherapy with any given antihypertensive drug are only ≈50%, 3 and those who fail to respond to 1 category (eg, those affecting renin-angiotensin system) class are more likely to respond to a drug with an alternate mechanism (≈75% response rate). 4, 5 Selection of the initial antihypertensive therapy is essentially by trial and error. The difficulty in determining the most appropriate antihypertensive drug for a specific patient likely contributes to the fact that less than half of the hypertensive patients in the United States (and worldwide) currently have their blood pressure (BP) controlled. 6 Pharmacogenomics offers the clinical promise of individualization of therapy based on a person's genetic makeup.
H ypertension (HTN) places more than 76 million Americans (and ≈1 billion individuals worldwide) at substantially increased risk for stroke, coronary heart disease (including heart attack), renal failure, and heart failure, and it is the most common chronic disease for which medications are prescribed. 1 Five drug classes are considered appropriate first-line therapy for HTN and are often defined by their effect on the reninangiotensin system (β-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers) or sodium and calcium (thiazide diuretics and calcium channel blockers).
To date, 39 single nucleotide polymorphisms (SNPs) have been associated with BP or HTN in genome-wide association studies (GWAS) and meta-analyses in whites. [7] [8] [9] [10] [11] Our hypothesis is that the loci/SNPs associated with BP/HTN are also associated with BP response to antihypertensive drugs. To test this hypothesis, we assessed in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study the association of these loci with BP response to 2 first-line antihypertensives with contrasting pharmacological mechanisms: atenolol (a cardioselective β-blocker) and hydrochlorothiazide (HCTZ, a thiazide diuretic).
Methods

Participants
The PEAR study (n=768) was a randomized, multicenter clinical trial examining the role of genetic variability on BP response to HCTZ and atenolol. 12 Men and women of any race between the ages of 17 and 65 years with essential HTN (clinic diastolic BP ≥90 mm Hg, ≤110 mm Hg) were recruited to participate at the University of Florida (Gainesville, FL), Mayo Clinic (Rochester, MN), and Emory University (Atlanta, GA). The institutional review boards at each institution approved the protocol, and each participant provided informed written consent before entry into the study. Those currently treated had their antihypertensive drug therapy tapered (as necessary) and discontinued. The mean washout period was 28 days. This washout period was deemed to sufficiently balance risks of nontreatment with a sufficient period to allow return to untreated BP because postwashout BP levels in previously treated participants were nearly identical to baseline BP of those who entered the trial untreated.
Participants were randomized to receive either HCTZ 12.5 mg daily or atenolol 50 mg daily for 3 weeks, followed by dose titration to 25 mg and 100 mg daily, respectively, for systolic BP (SBP) >120 mm Hg and diastolic BP (DBP) >70 mm Hg. After 9 weeks, BP response to monotherapy was assessed. The second study drug (alternate drug) was added in those patients with SBP >120 mm Hg or DBP >70 mm Hg (>90% for both randomization arms), with dose titration after 3 weeks and response assessment after 6 more weeks, as in the first portion of the study. Participants were not given sodium restrictions, but were counseled to maintain consistent dietary intakes.
BP Phenotype
The primary BP phenotype for PEAR was home BP measured with an automated device (MicroLife 3AC1-PC, Minneapolis, MN) provided to each participant. The device was set to measure BP in triplicate with each activation and to store the average SBP and DBP and the time of each set of measurements. Participants were required to take readings daily in the seated position in triplicate upon rising and before retiring at least 5 of 7 days before the 3 visits: baseline (before randomization), assessment visit after monotherapy, and assessment visit after add-on therapy. All BP readings since the previous study visit were downloaded to the computer by study coordinators. Home BP response to monotherapy was the primary response phenotype because it exhibits less variability and is superior to office BP in the prediction of prognosis.
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Genotyping and QC Steps
Thirty-nine SNPs/loci were identified from the BP GWAS studies and meta-analyses that have been published up to October 2011 [7] [8] [9] [10] [11] as signals that reached genome-wide significance of P<5×10 -8 . In PEAR participants, genotypes of 37 SNPs (exact SNPs for 26 loci and proxies for 11 loci) were obtained from Illumina Human 50K cardiovascular Beadchip or Omni1M quad GWAS Beadchip. Two SNPs (rs4590817 and rs319690) were not covered on either platform (online-only Data Supplement Table I ).
Illumina Human CVD 50K Array
The Human CVD 50k SNP array 16 was a customized genecentric array including ≈2100 genes and ≈50 000 SNPs genotyped using the Infinium II Assay (Illumina, San Diego, CA). Genotypes were called using GenomeStudio software version 2011.1 and the Genotyping Module version 1.9 calling algorithm (Illumina, San Diego, CA).
Participants were excluded if sample genotype call rates were <95%, and SNPs were excluded if genotype call rates were <90%. The genotype data were not reclustered after QC filters, but the genotype and sample call rates were recalculated after QC. Sample contamination was detected by checking sex mismatches using X-chromosome genotype data, and cryptic relatedness was estimated by pairwise identityby-descent analysis implemented using PLINK (http://pngu. mgh.harvard.edu/purcell/plink/). After all QC procedures, the total SNP call rate in the remaining individuals was 99.799%. Hardy-Weinberg equilibrium was assessed with χ 2 test if 1 df.
Illumina Omni1M Quad GWAS Chip
The Human Omni1M quad GWAS chip also used Infinium II assay, and genotypes were called using BeadStudio software and GenTrain2 calling algorithm. The same QC procedures were carried out for the GWAS genotype data. After the QC procedures, the total SNP call rate in the remaining individuals was 99.519%. Principal component analysis was performed to assess the ancestral background. Participants' self-identified race information was confirmed with principal component analysis for genetic ancestry, and 464 participants were confirmed as European descendants and 304 as African descendants. Seven hundred fifty-nine participants were included in this analysis, including 461 whites and 298 blacks. Nine participants were excluded as a result of genotype QC issues or missing genotypes.
Statistical Methods
The primary analysis was performed in whites because the GWAS signals selected for this analysis arose from studies in whites. Associations of these SNPs with SBP and DBP responses to atenolol or HCTZ monotherapy were evaluated using linear regression, adjusting for baseline BP, age, sex, and the first 2 principal components for ancestry that correspond to European and African ancestry, respectively. Previous analysis 17 of BP response in PEAR established that age, sex, and baseline BP were significant demographic predictors of BP response, whereas common covariates such as body mass index and smoking were not associated with BP response and therefore not included as covariates. P values <0.0014 (0.05/37) were considered statistically significant. Additive mode of inheritance was assumed where the SNPs were coded as 0, 1, and 2 in the linear regression model. For the SNPs with P<0.05 in whites, the association analysis of the index SNPs and the surrounding 100-kb region was also performed in black participants to assess whether an association with the same direction was present in participants with a different ancestral background. Particular attention was also given to SNPs with association in the opposite direction for HCTZ and atenolol, because the counterbalancing mechanisms targeted by these agents led to good responders to one of the drugs being poor responders to the other. 18 For the SNPs that reached nominal significance, genetic scores were constructed by summing the alleles with the best BP response for inclusion in regression models (using the BP-lowering allele as the coded allele). A weighted score method was also assessed based on the coefficient of BP response for each SNP. The participants with any missing genotypes would not get a score and therefore were not included in the score analysis. Because the BP response alleles are different for atenolol and HCTZ, separate genetic scores were constructed for atenolol and HCTZ monotherapy. To validate the association of the scores with the BP responses, we generated the distribution of the regression test statistics empirically by repetitively permutating the BP responses. The relationship between the BP responses and the scores was randomly shuffled 1,000×, and a regression model was fit for each permutation. The raw P values of the scores predicting BP response of the raw data were then compared with the empirical distribution of 1,000 P values from the permutations. Analysis was performed using PLINK. 19 The genetic score analysis and permutation test were performed in SAS version 9.3 (Cary, NC).
Results
The PEAR participants were white (60%) and black (40%) hypertensive individuals, and 53% were women. Participants had a mean age of 48.8±9.2 years, and most were overweight or obese. The baseline characteristics of the 461 white and 298 black participants assigned to atenolol and HCTZ treatment are presented in Table 1 .
After an average of 9 weeks of atenolol monotherapy, the mean BP response was −11.0±9.4/−9.9±6.4 mm Hg in white participants and −3.1±10.6/−4.2±6.7 mm Hg in black participants. The mean BP response after HCTZ monotherapy was −7.7±8.1/−4.3±5.3 mm Hg in whites and −12.0±9.7/7.1 ± 6.5 mm Hg in blacks. The distributions of BP response in onlineonly Data Supplement Figure I demonstrate the large interindividual variability in BP response to atenolol and HCTZ in both race groups.
Genotypes for 37 of the 39 BP/HTN SNPs were available for PEAR participants from the 2 genotyping platforms. No SNPs deviated from Hardy-Weinberg equilibrium in whites or blacks.
When the association of these 37 SNPs with SBP and DBP response to atenolol or HCTZ monotherapy was assessed, none of the SNPs reached a priori α of 0.0014, although 6 SNPs achieved nominal significance (P<0.05). The associations of these SNPs with monotherapy BP response in whites are summarized in Table 2 . The most interesting was an intergenic SNP rs1458038 near FGF5, which was associated with BP response to atenolol and HCTZ monotherapy, with genotype effects in the opposite direction (Figure 1 ). Participants with TT and TC genotypes of this common SNP responded better to atenolol than those with CC genotype (with SBP/ DBP response of −12.9/−11.6 mm Hg, −12.3/−10.6 mm Hg, and −8.9/−8.5 mm Hg for TT, TC, and CC, respectively; P=0.0067 for SBP and P=0.018 for DBP), whereas the direction of association was the opposite for response to HCTZ (with −5.4/−2.6 mm Hg, −7.5/−4.3 mm Hg, −8.7/−4.8 mm Hg for TT, TC, and CC, respectively; P=0.039 for SBP and P=0.069 for DBP).
The genetic score composed of the 4 BP-lowering alleles in response to atenolol monotherapy showed stronger association, with P=3.3×10 -6 for SBP response and P=1.6×10 -6 for DBP response. The raw P values are smaller than the minimum P values from the 1000 permutations (online-only Data Supplement Table II) , and thus the significance was validated through the permutation tests. The BP responses to atenolol monotherapy by genetic score are shown in Figure 2 (A for SBP response and B for DBP response). In white hypertensive patients with only 1 of the 4 BP-lowering alleles, the average BP response to atenolol monotherapy was −4.0/−3.3 mm Hg, whereas the average BP response was −18.6/−23.5 mm Hg in those with 6 BP-lowering alleles. This genetic score explained 8.5% of SBP response and 8.2% of DBP response to atenolol monotherapy, respectively.
The association of the genetic score composed of the 3 BP-lowering alleles for HCTZ monotherapy was also stronger than those for the individual SNPs, with P of 0.0006 for SBP response and P of 0.0003 for DBP response to HCTZ monotherapy. The raw P values are <0.01 based on the empirical distribution of the permutation test. The BP responses to HCTZ monotherapy by genetic score are shown in Figure 3 (A for SBP responses and B for DBP responses). This genetic score explained 4.3% for SBP response and 5.3% for DBP response to HCTZ monotherapy. The weighted scores yielded almost identical results, and because of the simplicity of the unweighted scores, this model was preferred.
Associations of these 6 SNPs and the SNPs in the same region with the BP response in blacks were also evaluated. None of the white index SNPs achieved nominal significance in blacks, with a directional effect the same as in whites. rs871606 near CHIC2 was marginally associated with DBP response to atenolol monotherapy in blacks (DBP, P=0.06, β=1.89), with the same direction of effect as in whites. One SNP had a directionally opposite effect of association in blacks as in whites: the C allele of rs3184504 in SH2B3 (nonsynonymous, T>C, Trp>Arg) was associated with better BP reduction in whites in response to HCTZ (Table 2 ). However, in blacks treated with HCTZ, the C allele of this SNP is associated with a slight increase in BP (DBP, P=0.047, β=0.21).
When the 100-kb regions flanking the index SNPs were evaluated in blacks, 2 different SNPs (rs12069113, rs12076902) near MOV10 were found to be nominally associated with BP response to atenolol (DBP, P=0.042 and 0.02, respectively; online-only Data Supplement Figure II) . These 2 SNPs were in high linkage disequilibrium with each other (r 2 =0.78 and 1 in whites and blacks, respectively) but in very low linkage disequilibrium with the white index SNP, rs2932538, in both populations (r 2 =0.01 and 0.02 in whites and blacks, respectively). No stronger signals were found in blacks in the regions flanking the white index SNPs. There was also no evidence that the genetic scores for either atenolol or HCTZ BP-lowering alleles in whites are associated with BP response in blacks (P=0.49 for SBP and P=0.49 for DBP in response to HCTZ and P=0.59 for SBP and P=0.42 for DBP in response to atenolol monotherapy, respectively).
Discussion
Among 37 SNPs previously documented to influence BP, none achieved a priori α values for association with BP response to atenolol or HCTZ. However, 6 SNPs were nominally associated with BP response in whites. Two of these SNPs were also marginally associated with response in blacks for the same drug, one with the same direction of effect and the other with the opposite direction of effect. Lack of association of these index SNPs in blacks was not surprising because of different LD structures between these 2 populations.
Of interest is that gene score analyses for both atenolol and HCTZ BP-lowering alleles revealed that the scores were more strongly associated with the BP response than the individual SNPs. This finding is not surprising for a phenotype with multiple genetic contributors, as is expected for the antihypertensive response. The percentage of variance of BP response explained by these genetic scores ranged from 4.3% to 8.5%, which are larger effect sizes than the genetic risk scores constructed to predict the untreated BP in the HTN GWAS studies (≈116 independent loci collectively explain ≈2.2% of the phenotypic variance for SBP and DBP). 7 This result is consistent with numerous studies indicating that pharmacogenetic effect sizes are larger than disease genetic effect sizes. These data also provide insight into how genetic risk scores might be built to guide selection of an antihypertensive drug based on genetic information.To ensure that the associations of these SNPs were not due to multicollinearity with the baseline BP, we also tested the association without adjusting for baseline BP and found that the results were essentially identical. In addition, we also tested the association of these SNPs with baseline BP, and not surprisingly, given our small sample size and limited BP range (DBP 90-110 mm Hg), there was no significant association with baseline BP. This finding indicates that the associations presented are not likely to be a result of collinearity with the baseline BP.
The finding of SNP rs1458038 near FGF5 is perhaps the most intriguing single SNP finding because it was associated with BP responses to both atenolol and HCTZ, but with the effects in opposite directions. This result represents a form of replication because the HCTZ-treated participants were an independent group, and the opposite direction of effect is consistent with our expectations on genetic associations for the 2 drugs. The effect sizes of BP response for this SNP ranged from 1.0 to 2.5 mm Hg per allele (double that for variant homozygotes). Differences of 2 to 3 mm Hg SBP reduction have been shown to reduce stroke risk by 20% to 30% in a meta-analysis of 9 randomized controlled trials of antihypertensive drugs, 20 suggesting that the associations noted here would be considered clinically significant.
In an HTN GWAS study, 7 the T allele of rs1458038 near FGF5 was associated with higher BP and higher risk for HTN in white individuals. This SNP was also strongly associated with BP in East Asians and South Asians and only marginally in blacks. Our study indicates that white hypertensive individuals with the risk allele for HTN (T) may respond better to atenolol than to HCTZ. FGF5 encodes fibroblast growth factor 5, which is involved in a variety of biological processes, including embryonic development, cell growth, morphogenesis, tissue repair, tumor growth, and invasion. It is not immediately clear how this gene is involved in BP regulation, but the association with atenolol responsiveness suggests that this gene may be a marker for high sympathetic nervous system and renin-angiotensin activity, and unraveling the function of this gene may provide additional insights.
Conclusions
We tested 37 SNPs/loci previously associated with BP in GWAS for association with antihypertensive response. Our results showed that the genetic loci associated with BP and HTN are not strongly associated with the BP response to commonly prescribed antihypertensives individually, with the most compelling data for a single SNP being one near FGF5. However, collectively, a selection of these loci may contribute moderately to the BP response to the antihypertensives. This finding highlights the potential for building response scores for clinical prediction of response.
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